Qiaoshuai Lan

Hong Kong Science and Technology Parks Corporation — China

Medicine · Health Sciences

17h-index3.1kcitations27works13.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(21), COVID-19 Clinical Research Studies(11), Viral gastroenteritis research and epidemiology(6), interferon and immune responses(6), Animal Virus Infections Studies(5)

Publications27 total

Organoid-based neutralization assays reveal a distinctive profile of SARS-CoV-2 antibodies and recapitulate the real-world efficacy
Proceedings of the National Academy of Sciences·2025· 4 citedOpen Access
Human respiratory organoids sustained reproducible propagation of human rhinovirus C and elucidation of virus-host interaction
Nature Communications·2024· 16 citedOpen Access
Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1
Signal Transduction and Targeted Therapy·2024· 19 citedOpen Access
Clinical development of antivirals against SARS-CoV-2 and its variants
Current Research in Microbial Sciences·2023· 8 citedOpen Access
Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein
Communications Biology·2022· 12 citedOpen Access
A core epitope targeting antibody of SARS-CoV-2
Protein & Cell·2022Open Access
Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases
Journal of Medical Virology·2022· 28 citedOpen Access
A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern
Viruses·2022· 19 citedOpen Access
The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants
Viruses·2022· 14 citedOpen Access
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
Cell Research·2022· 40 citedOpen Access
Coronavirus Entry Inhibitors
Advances in experimental medicine and biology·2022· 5 cited
Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
Cell Discovery·2021· 24 citedOpen Access
25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses
International Journal of Molecular Sciences·2021· 21 citedOpen Access
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
Acta Pharmaceutica Sinica B·2021· 35 citedOpen Access
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation
Signal Transduction and Targeted Therapy·2021· 66 citedOpen Access
A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses
Cell & Bioscience·2021· 18 citedOpen Access
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity
Journal of Virology·2021· 110 citedOpen Access
Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
Microbes and Infection·2021· 2 citedOpen Access
Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus Infection
Journal of Medicinal Chemistry·2021· 17 cited
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
Signal Transduction and Targeted Therapy·2020· 363 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Lu Lu(23), Shuai Xia(21), Shibo Jiang(21), Wei Xu(17), Qian Wang(9), Lijue Wang(7), Fanke Jiao(7), Chao Wang(6), Yun Zhu(6), Jie Zhou(6), Zezhong Liu(5), Jing Pu(5), Fei Sun(4), Yanxing Cai(4), Meiqin Liu(3), Shuwen Liu(3), Zheng‐Li Shi(3), Xinling Wang(3), Youhua Xie(3), Jasper Fuk‐Woo Chan(3)